106 related articles for article (PubMed ID: 9163613)
1. Low-dose aspirin in polycythaemia vera: a pilot study. Gruppo Italiano Studio Policitemia (GISP).
Br J Haematol; 1997 May; 97(2):453-6. PubMed ID: 9163613
[TBL] [Abstract][Full Text] [Related]
2. Aspirin in polycythemia vera and essential thrombocythemia: current facts and perspectives.
Landolfi R; Patrono C
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():83-6. PubMed ID: 8951777
[TBL] [Abstract][Full Text] [Related]
3. European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP): a randomized trial.
Landolfi R; Marchioli R
Semin Thromb Hemost; 1997; 23(5):473-8. PubMed ID: 9387206
[TBL] [Abstract][Full Text] [Related]
4. Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia.
Squizzato A; Romualdi E; Middeldorp S
Cochrane Database Syst Rev; 2008 Apr; (2):CD006503. PubMed ID: 18425953
[TBL] [Abstract][Full Text] [Related]
5. Platelet thromboxane inhibition by low-dose aspirin in polycythemia vera: Ex vivo and in vivo measurements and in silico simulation.
Petrucci G; Giaretta A; Ranalli P; Cavalca V; Dragani A; Porro B; Hatem D; Habib A; Tremoli E; Patrono C; Rocca B
Clin Transl Sci; 2022 Dec; 15(12):2958-2970. PubMed ID: 36200184
[TBL] [Abstract][Full Text] [Related]
6. Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, noninferiority trial.
Angiolillo DJ; Hwang C; Datto C; Desai B; Sostek M
Clin Ther; 2011 Dec; 33(12):1883-93. PubMed ID: 22078153
[TBL] [Abstract][Full Text] [Related]
7. The use of aspirin in polycythaemia vera and primary thrombocythaemia.
Willoughby S; Pearson TC
Blood Rev; 1998 Mar; 12(1):12-22. PubMed ID: 9597194
[TBL] [Abstract][Full Text] [Related]
8. Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients.
Santilli F; Romano M; Recchiuti A; Dragani A; Falco A; Lessiani G; Fioritoni F; Lattanzio S; Mattoscio D; De Cristofaro R; Rocca B; Davì G
Blood; 2008 Aug; 112(4):1085-90. PubMed ID: 18541722
[TBL] [Abstract][Full Text] [Related]
9. Thromboxane-dependent platelet activation in vivo precedes arterial thrombosis in thrombocythaemia: a rationale for the use of low-dose aspirin as an antithrombotic agent.
van Genderen PJ; Prins FJ; Michiels JJ; Schrör K
Br J Haematol; 1999 Mar; 104(3):438-41. PubMed ID: 10086775
[TBL] [Abstract][Full Text] [Related]
10. [Defects in the prostaglandin system. IX. Lipoxygenase defect of thrombocytes in a patient with polycythemia vera].
Sinzinger H; Gisslinger H; Linkesch W; Peskar BA
Wien Klin Wochenschr; 1990 Feb; 102(3):74-6. PubMed ID: 2107637
[TBL] [Abstract][Full Text] [Related]
11. Transdermal modification of platelet function: an aspirin patch system results in marked suppression of platelet cyclooxygenase.
McAdam B; Keimowitz RM; Maher M; Fitzgerald DJ
J Pharmacol Exp Ther; 1996 May; 277(2):559-64. PubMed ID: 8627531
[TBL] [Abstract][Full Text] [Related]
12. Transdermal modification of platelet function. A dermal aspirin preparation selectively inhibits platelet cyclooxygenase and preserves prostacyclin biosynthesis.
Keimowitz RM; Pulvermacher G; Mayo G; Fitzgerald DJ
Circulation; 1993 Aug; 88(2):556-61. PubMed ID: 8339418
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.
Capone ML; Tacconelli S; Sciulli MG; Grana M; Ricciotti E; Minuz P; Di Gregorio P; Merciaro G; Patrono C; Patrignani P
Circulation; 2004 Mar; 109(12):1468-71. PubMed ID: 15037526
[TBL] [Abstract][Full Text] [Related]
14. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance".
Santilli F; Rocca B; De Cristofaro R; Lattanzio S; Pietrangelo L; Habib A; Pettinella C; Recchiuti A; Ferrante E; Ciabattoni G; Davì G; Patrono C
J Am Coll Cardiol; 2009 Feb; 53(8):667-77. PubMed ID: 19232899
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin.
Pettinella C; Romano M; Stuppia L; Santilli F; Liani R; Davì G
Thromb Haemost; 2009 Apr; 101(4):687-90. PubMed ID: 19350112
[TBL] [Abstract][Full Text] [Related]
16. Risk factors and prevention of vascular complications in polycythemia vera.
Barbui T; Finazzi G
Semin Thromb Hemost; 1997; 23(5):455-61. PubMed ID: 9387204
[TBL] [Abstract][Full Text] [Related]
17. Umbilical cord serum levels of thromboxane B2 in term infants of women who participated in a placebo-controlled trial of low-dose aspirin.
Parker CR; Hauth JC; Goldenberg RL; Cooper RL; Dubard MB
J Matern Fetal Med; 2000; 9(4):209-15. PubMed ID: 11048830
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of low-dose aspirin in polycythemia vera.
Landolfi R; Marchioli R; Kutti J; Gisslinger H; Tognoni G; Patrono C; Barbui T;
N Engl J Med; 2004 Jan; 350(2):114-24. PubMed ID: 14711910
[TBL] [Abstract][Full Text] [Related]
19. Incomplete thromboxane inhibition with 100 mg of intravenous acetylsalicylic acid in patients with acute ST elevation myocardial infarction: a placebo-controlled pilot trial.
Ziegler BK; Kristensen SD; Vissinger H; Jensen HK; Nielsen HK; Husted SE
Thromb Res; 2001 Nov; 104(3):175-80. PubMed ID: 11672759
[TBL] [Abstract][Full Text] [Related]
20. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA
J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
